Jazz Pharmaceuticals

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Jazz Pharmaceuticals achieves record revenue in Q4 2022

Jazz Pharmaceuticals delivered strong financial performance in Q4 2022, driven by key products and a focus on operational efficiency.
The company's pipeline expansion, strategic focus, and differentiated products position it well for future growth.
While facing challenges in sales guidance and market education, Jazz Pharmaceuticals has opportunities for growth through new molecules and market expansion.
Overall, Jazz Pharmaceuticals remains optimistic about its growth trajectory, supported by product differentiation and strategic initiatives.

Jazz Pharmaceuticals excels in Q1 2023, eyes growth opportunities

Jazz Pharmaceuticals demonstrated strong financial performance and operational excellence in Q1 2023, driven by key products like Xywav and Epidiolex.
While facing challenges in patient adoption and prescriber education, the company remains focused on strategic investments and sustainable growth initiatives.
With a robust pipeline, revenue growth opportunities, and a commitment to patient impact, Jazz Pharmaceuticals is well-positioned to achieve its Vision 2025 goals.

Jazz Pharmaceuticals excels in Q2, eyes pipeline growth opportunities

Jazz Pharmaceuticals demonstrated strong commercial performance and financial growth in Q2 2023, driven by key product successes and pipeline advancements.
While facing operational challenges, the company's strategic strengths in capital allocation, R&D focus, and market positioning bode well for future growth.
With a clear focus on Vision 2025 targets, Jazz Pharmaceuticals remains confident in its ability to navigate challenges and capitalize on growth opportunities.

Jazz Pharmaceuticals reports strong Q3 performance and eyes global expansion

Jazz Pharmaceuticals' Q3 earnings call reflects robust sales growth, strategic initiatives to drive key products towards blockbuster status, and a focus on innovation in therapeutic treatments.
The company's strengths in revenue diversification, global expansion plans for Epidiolex, and confidence in upcoming treatments position it well for sustained growth in the pharmaceutical market.
While facing challenges in market competition and revenue dynamics, Jazz Pharmaceuticals is poised to capitalize on opportunities in global market expansion, new oncology assets, and innovative treatment approaches.

Jazz Pharmaceuticals excels in Q4, eyes growth through innovation

Jazz Pharmaceuticals delivered strong financial results, driven by key products like Xywav, Epidiolex, and Rylaze, showcasing revenue growth and profitability.
The company's focus on oncology and neuroscience, with late-stage catalysts and global expansion plans, highlights a commitment to innovation and market leadership.
While facing challenges in a competitive landscape, Jazz Pharmaceuticals remains poised for growth through strategic initiatives, R&D advancements, and product differentiation.
Overall, Jazz Pharmaceuticals' performance, strengths, and opportunities position it well for sustained growth and value creation in the pharmaceutical industry.

Jazz Pharma excels in Q1 2024, eyes growth in oncology and neuroscience

Jazz Pharmaceuticals delivered strong Q1 2024 results, driven by revenue growth and key product performance in oncology and neuroscience.
The company's disciplined capital allocation and strategic investments position it well for future growth and innovation in its pipeline.
While facing challenges in clinical trials and competitive markets, Jazz Pharma remains focused on leveraging strengths and seizing growth opportunities.

Jazz Pharmaceuticals achieves record revenues, updates guidance for 2024

Jazz Pharmaceuticals delivered exceptional financial performance in Q2 2024 with record revenues.
Key products showed strong sales growth, reflecting market acceptance and demand.
The company's focus on long-term value creation through investments and guidance update is notable.
Challenges include maintaining growth momentum and successful data readouts from late-stage programs.

Jazz Pharmaceuticals excels in Q3 with record sales and growth

Jazz Pharmaceuticals' Q3 2024 performance reflects strong revenue growth and operational resilience, driven by key products and ongoing innovation efforts.
While facing challenges like revenue impact for Rylaze, the company remains focused on normalizing demand and advancing its pipeline programs.
With a solid financial foundation and a strategic focus on high-potential areas, Jazz Pharmaceuticals is well-positioned to capitalize on growth opportunities.
By affirming revenue guidance, investing in innovation, and exploring business development prospects, Jazz Pharmaceuticals demonstrates a commitment to long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Jazz Pharmaceuticals (JAZZ) to Report Q2 Results: Wall Street Expects Earnings Growth

Jazz Pharmaceuticals' current valuation is significantly lower than the sector average, despite strong margins and a positive growth outlook, presenting a potential investment opportunity. The company is making progress in its clinical trials and is diversifying its product offerings to mitigate the impact of generic drugs entering the market. Despite some challenges, such as a lengthy regulatory approval process for a new product, Jazz Pharmaceuticals is well-positioned to achieve its target of $5 billion in revenues by 2025.

Jazz Pharmaceuticals: Depressed Valuation Opens Up Potential

DUBLIN , July 21, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the marketing authorization of JZP458 (a recombinant Erwinia asparaginase or crisantaspase) for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase.

Jazz Pharmaceuticals Receives CHMP Positive Opinion for JZP458 (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

The mean of analysts' price targets for Jazz (JAZZ) points to a 54.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Jazz (JAZZ) Could Surge 54.74%: Read This Before Placing a Bet

Kelly Services

Livent Corp

Dave & Buster's

Urban Outfitters

A financial advisor can help you understand the advantages and disadvantages of investment properties.

Uncover Value Opportunities With These 5 Earnings Yield Gems

LM Ericsson Telefon

Penn Entertainment

Royalty Pharma

While a very few are just now coming off of all-time highs (Nvidia, among others), some are recently all the way down to new 52-week lows.

NASDAQ Stocks Hitting New 52-Week Lows: 4 Stocks To Watch

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?

Scotts Miracle-Gro

Do you intend to invest in marijuana stocks in 2023?  Over the last decade, the cannabis industry has grown incredibly, transitioning from a taboo subject to a respectable and wealthy corporate sector. As the global cannabis market grows in 2023, investors' focus will shift to ancillary cannabis stocks, which will be important in supporting and propelling the industry forward.

Top Pharmaceutical And Ancillary Cannabis Stocks For June 2023

Zymeworks Inc

Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity, confirmed objective response rate (cORR) of 41.3%, median duration of response (DOR) of 12.9 months, and median progression-free survival (PFS) of 5.5 months  (median study follow-up time of 12.4 months) Biliary tract cancers (BTC) are an aggressive group of cancers with no currently approved HER2-targeted treatment option Jazz to host KOL investor webcast June 2, 2023, at 6:45 p.m. CT to review zanidatamab BTC data DUBLIN and VANCOUVER, BC , June 2, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today presented positive pivotal trial data, including new data on progression-free survival (PFS), from the Phase 2b HERIZON-BTC-01 trial of the bispecific antibody zanidatamab in previously treated HER2-amplified biliary tract cancers (BTC).

Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers

Seven abstracts emphasize Jazz's commitment to advancing the care and understanding of debilitating sleep disorders such as narcolepsy and idiopathic hypersomnia DUBLIN , May 31, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that seven abstracts featuring new data from across its sleep medicine portfolio will be presented at SLEEP 2023, the 37th annual meeting of the Associated Professional Sleep Societies (APSS) being held June 3-7, 2023. Presentations include four posters featuring real-world data on Xywav® (calcium, magnesium, potassium, and sodium oxybates), the first and only low-sodium oxybate, for the treatment of narcolepsy patients with cataplexy and/or excessive daytime sleepiness (EDS) and adult patients with idiopathic hypersomnia.

Jazz Pharmaceuticals Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023

DUBLIN , May 30, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2023 Goldman Sachs Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, June 13, 2023, at 3:20 p.m.

Jazz Pharmaceuticals to Participate in the 2023 Goldman Sachs Global Healthcare Conference

Zanidatamab data to be featured in oral presentation at ASCO 2023 Webcast to follow on June 2, 2023 at 6:45 p.m. CT DUBLIN , May 25, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a webcast to review the zanidatamab biliary tract cancers (BTC) data being featured in an oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2023.

Jazz Pharmaceuticals to Host Zanidatamab KOL Investor Webcast on June 2, 2023

Jazz (JAZZ) reports dismal first-quarter results as earnings and sales miss expectations. The company reaffirms its financial guidance for 2023.

Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Andrea Flynn - VP & Head, IR Bruce Cozadd - Co-Founder, Chairman & CEO Daniel Swisher - President & COO Robert Iannone - EVP & Global Head, Research & Development Renee Gala - EVP & CFO Kim Sablich - EVP & GM, US Conference Call Participants Marc Goodman - SVB Securities Jason Gerberry - Bank of America Merrill Lynch Joseph Thome - TD Cowen Jeff Hung - Morgan Stanley Gregory Fraser - Truist Securities Balaji Prasad - Barclays Bank Ashwani Verma - UBS Brandon Folkes - Cantor Fitzgerald & Co. Ami Fadia - Needham & Company David Amsellem - Piper Sandler & Co. Gregory Renza - RBC Capital Markets Madhu Kumar - Goldman Sachs Group Operator Good day, and thank you for standing by. Welcome to the Q1 2023 Jazz Pharmaceuticals Earnings Conference Call.

Jazz Pharmaceuticals PLC (JAZZ) Q1 2023 Earnings Call Transcript

The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, Jazz (JAZZ) Q1 Earnings: A Look at Key Metrics

Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $3.95 per share, missing the Zacks Consensus Estimate of $4.26 per share. This compares to earnings of $3.73 per share a year ago.

Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates

Focus on commercial execution drove 1Q23 total revenues of $892.8 million Continued adoption of Xywav ® ; net product sales increased 49% 1Q23 compared to 1Q22 Confident in blockbuster potential of Epidiolex ® ; net product sales increased 20% 1Q23 compared to 1Q22 Strong Rylaze ®  demand drove 58% increase in net product sales 1Q23 compared to 1Q22 Enhanced pipeline positioned to deliver at least three late-stage data readouts by the end of 2024 DUBLIN , May 10, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2023, affirmed 2023 financial guidance and provided business updates. "This quarter, we once again delivered strong commercial results, advanced our efforts to unlock the tremendous potential of our pipeline and built on our record of driving operational excellence.

Jazz Pharmaceuticals Announces First Quarter 2023 Financial Results and Affirms 2023 Financial Guidance

DUBLIN , May 2, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2023 RBC Capital Markets Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, May 16, 2023, at 4:05 p.m.

Jazz Pharmaceuticals to Participate in the 2023 RBC Capital Markets Global Healthcare Conference

Data from multiple studies of investigational bispecific drug zanidatamab, including pivotal Phase 2 biliary tract cancers (BTC) trial results, demonstrate breakthrough HER2-targeted pan-tumor potential Nine abstracts accepted for presentation, including two oral presentations, reinforce Jazz's growing leadership in oncology and commitment to patients through clinically beneficial treatments and novel research Company to host investor webcast on June 2, 2023, to review zanidatamab BTC data presentation DUBLIN , April 27, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present nine abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6, 2023. Presentations include clinical data from trials of zanidatamab, Zepzelca® (lurbinectedin) and Vyxeos® (daunorubicin and cytarabine).

Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline and Advances in Current Product Portfolio at ASCO 2023

DUBLIN , April 26, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 first quarter financial results on Wednesday, May 10, 2023, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m.

Jazz Pharmaceuticals to Report 2023 First Quarter Financial Results on May 10, 2023

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Eleven abstracts emphasize Jazz's leadership in neuroscience and commitment to advance understanding of sleep disorders, epilepsy and movement disorders Three oral presentations share meaningful data results in idiopathic hypersomnia and essential tremor DUBLIN , April 19, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eleven abstracts from across its neuroscience portfolio and pipeline, including three oral presentations, will be featured at the 75th Annual American Academy of Neurology Meeting (AAN) being held April 22-27, 2023 in Boston. "Our presence at the 2023 AAN Annual Meeting further reflects Jazz's scientific leadership in developing therapies for debilitating sleep disorders and rare epilepsy syndromes that advance treatment for people living with these conditions," said Kelvin Tan, MB BCh, MRCPCH, senior vice president and chief medical officer of Jazz Pharmaceuticals.

Jazz Pharmaceuticals to Present Advancements in Neuroscience at American Academy of Neurology Annual Meeting

Innovative Industrial Properties

Are Pot Stocks On Your List For April? The post Top Pot Stocks For Long Term Investing? 3 To Watch In April appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Top Pot Stocks For Long Term Investing? 3 To Watch In April

Jazz (JAZZ) Up 0.4% Since Last Earnings Report: Can It Continue?

Support to include dedicated educational website, science advisory panel, patient video series and strategic alliance across sleep patient advocacy organizations Research shows that sleep disorders are associated with increased risks of cardiovascular comorbidities, including those with narcolepsy being two- to three-times more likely to have a stroke or heart attack than people without narcolepsy DUBLIN , March 30, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced an expansion of its support of the American Heart Association (Association) to provide the sleep disorder community an in-depth understanding of the cardiovascular risks associated with these debilitating disorders. Through this initiative, the Association aims to help people living with sleep disorders determine when professional help may be appropriate and healthcare professionals recognize ways to improve heart health for the patients they treat.

News for Jazz Pharmaceuticals Stock (JAZZ)